Roxadustat

HIF-PHI inhibitor

Roxadustat is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH), with an IC50 value of 591.4 nM. This compound is primarily used to treat anemia associated with chronic kidney disease (CKD) by stimulating erythropoiesis.

Key features and applications include:

- **HIF-PH Inhibition:** Inhibits HIF-PH enzymes, leading to increased levels of hypoxia-inducible factors (HIFs) and promoting erythropoietin production.
- Erythropoiesis Stimulation: Increases hemoglobin levels and red blood cell production. Used to treat symptomatic anemia in patients with chronic kidney disease, both dialysis-dependent and non-dialysis-dependent.
- Cancer Research: Investigated for its potential to reduce tumor growth by modulating the tumor microenvironment.

Relevant disease states include:

- Chronic Kidney Disease (CKD): Approved for the treatment of anemia associated with CKD.
- **Cancer:** Potential applications in reducing tumor growth and improving cancer treatment outcomes.

Ordering Information


Order Online »

ENZ-CHM356-0025 25mg

Manuals, SDS & CofA

View Online »

· GMP format available



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended. Solutions in DMSO

may be stored at -20°C for up to 2 months.

Handling Keep container tightly closed in a dry and well-ventilated place.

Short Term Storage -20°C

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name 2-[(4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid

Appearance Off-white or white solid.

CAS 808118-40-3

Couple Target HIF-PH

Couple Type Inhibitor

Formula $C_{19}H_{16}N_2O_5$

Identity Determined by NMR.

MW 352.35

Purity ≥99% (HPLC)

Solubility Soluble in DMSO (up to at least 25 mg/ml).

